Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Florica Therapeutics Inc. is prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 1 pending office action. This workload is assigned to 1 distinct examiner and 1 distinct art unit, indicating a specific technical focus for the company's current intellectual property efforts. This focus suggests that the company is currently advancing a specific innovation within the biotechnology sector. The involvement of 1 distinct art unit further confirms that the pending application is being reviewed within a narrow technical specialty.
CONSTANTINA E STAVROU is the busiest examiner for the portfolio with 1 busiest examiner pending action. This 1 action represents the entirety of the pending office actions for the company. Because there is 1 distinct examiner, the current prosecution is centralized within a technical review group. This centralized prosecution allows for a focused response to the examiner's specific requirements within the Biotechnology & Pharmaceuticals area. Practitioners should prioritize this 1 pending action as it represents the full scope of the company's current engagement with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17913403 | Neuronal diencephalon stem cells, preparation and uses for treatment and prevention of hormonal disorders and other diseases | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17913403 | Neuronal diencephalon stem cells, preparation and uses for treatment and prevention of hormonal disorders and other diseases | STAVROU, CONSTANTINA E | 1632 | §103 | Final Rejection | — | Pending | Sep 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial